02.10.2024, 4001 Zeichen
London (OTE) - Norgine (the "Company"), a leading European specialty
pharmaceutical
company, has today announced the appointment of Janneke van der Kamp
as its new Chief Executive Officer (CEO), effective from 1 January
2025. Current CEO, Chris Bath, has stepped down from his role
effective immediately.
This change in leadership will support and enhance the Company's
mission of bringing transformative medicines to patients and
consumers. It will further enable Norgine's strong growth trajectory,
focused on advancing existing brands, developing and commercialising
pipeline products, and leveraging the Norgine platform through
business development initiatives.
Peter Stein, Chairman of Norgine said: "On behalf of the Norgine
Board of Directors and shareholders, we are excited to welcome
Janneke to lead Norgine. She is a world class and proven strategic
leader with extensive experience in the pharmaceutical industry,
leading organisations and launching innovative products to transform
patient outcomes. With Janneke's appointment, we have attracted the
ideal leader for the next phase of Norgine's exciting growth. Janneke
brings to Norgine a deep understanding of the industry, unmatched
energy and passion for improving patients' and consumers' lives and a
commitment to creating value for shareholders, customers and
colleagues."
Janneke van der Kamp brings over two decades of experience in the
pharmaceutical industry and joins Norgine from Grünenthal, where she
is currently the Chief Commercial Officer. Before that, she served as
Head of Pharma Region Europe at Novartis, where she spent over 19
years in roles including General Manager, Global Neurosciences
Franchise Head, and Global Head of Product and Portfolio Strategy for
the entire Novartis Pharma portfolio. Janneke holds an M.Sc in
Chemistry and an MBA from INSEAD.
Janneke van der Kamp, incoming CEO of Norgine said: "I am
honoured and excited to serve as the next CEO of Norgine. This is an
outstanding business, with a great heritage and exciting future. What
excites me most is the opportunity to drive the next growth phase at
Norgine, with our market leading launch and growth Rx brands, the
tremendous Movicol consumer health franchise, and our ambitious plans
to accelerate licencing and acquisitions of innovative medicines. I
look forward to connecting with our patients, customers, partners
and, most of all, my new colleagues across Europe and ANZ."
Norgine's senior leadership has been expanded since the
investment of Goldman Sachs Alternatives in 2022 to support its
ambitious growth and transformation plans. The leadership team will
continue leading the business and has the full support of the Board.
About Norgine
Norgine is a uniquely positioned, specialty pharmaceutical and
consumer healthcare company, with over Ꞓ500 million of annual
revenues and a 120-year track record of bringing life-changing
products to patients and consumers across our core markets of Western
Europe, Australia and New Zealand.
Our integrated approach - strong commercial capabilities, deep
medical, regulatory and clinical expertise, in-house manufacturing,
robust supply networks, and best in class enabling functions -
ensures that we can deliver high-quality, transformative medicines
quickly and effectively to over 25 million patients annually.
Today's Norgine is a nimble, innovative, and high-performing
company that has been transformed by a relentless focus on
operational excellence. This focus will enable us to secure the
legacy of more than a century of innovation and doing the right thing
by our patients, as we push the boundaries and take strides into new
therapeutic areas.
NORGINE and the sail logo are trademarks of the Norgine group of
companies.
Logo - http://mma.prnewswire.com/media/597589/Norgine_Logo.jpg
View original content: https://www.prnewswire.co.uk/news-
releases/norgine-announces-appointment-of-new-ceo-janneke-van-der-
kamp-302265456.html
Digital press kit: http://www.ots.at/pressemappe/PR80824/aom
kapitalmarkt-stimme.at Podcast: Christoph Boschan fasst die Pro-Kapitalmarkt-Argumente zusammen
Aktien auf dem Radar:Agrana, Pierer Mobility, Kapsch TrafficCom, Immofinanz, CA Immo, Flughafen Wien, AT&S, EVN, DO&CO, OMV, Palfinger, Stadlauer Malzfabrik AG, Zumtobel, Oberbank AG Stamm, Amag, Erste Group, Österreichische Post, S Immo, Telekom Austria, Uniqa, VIG, Wienerberger, Warimpex, Amazon, Intel, RWE, Henkel, Hannover Rück, DAIMLER TRUCK HLD..., Fielmann, Volkswagen Vz..
Do&Co
Als Österreichisches, börsennotiertes Unternehmen mit den drei Geschäftsbereichen Airline Catering, internationales Event Catering und Restaurants, Lounges & Hotel bieten wir Gourmet Entertainment auf der ganzen Welt. Wir betreiben 32 Locations in 12 Ländern auf 3 Kontinenten, um die höchsten Standards im Produkt- sowie Service-Bereich umsetzen zu können.
>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner
Mehr aktuelle OTS-Meldungen HIER